NMOSDに対する生物学的製剤・ステロイドの安全性を徹底的に比較する

抄録

Now, patients with neuromyelitis optica spectrum disorder (NMOSD) who have suffered from the fear of relapses have hope for the future, with the increase in new treatment options for NMOSD ; newly approved biologics targeting complement C5 (eculizumab, ravulizumab), cytokine IL–6 (satralizumab), B cells (CD19 (inebilizumab) and CDC20 (rituximab)). On the other hand, NMOSD is a disease that requires long–term treatment. Therefore, the safety of the drugs must be continuously monitored. The safety considerations listed in the Risk Management Plan (RMP) include important identified risks, important potential risks, and important missing information. It is the duty of the physicians who prescribe these new drugs to contribute to updating this information through post–marketing surveillance (PMS) and to use the RMP materials to minimize the risks to patients with NMOSD.

This symposium focused on the long–term safety of biologics and steroids and aimed to update the safety information for each drug as of November 2024.